Supplementary Figure 5 from Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model
Year: 2023
Type: supplementary-materials
Abstract: PDF - 2987KB, Tumor growth was established by subcutaneous injection of parental HeLa cells into athymic nude mice (nu/nu) followed by the oral administration of tiplaxtinin at two different doses as described in Materials and Methods. Corn oil administered orally served as control. A, HeLa tumor sizes were recorded over five weeks. The relative tumor size was plotted as mean + SD from the three treatment groups per cell line (n=10/group). Treatment with tiplaxtinin (5 mg/kg and 20 mg/kg) was associated with a reduction in HeLa tumor burden. B, H&E and PAI-1 staining of HeLa tumors are shown (images 200X). A reduction in PAI-1 expression was noted in HeLa tumors treated with tiplaxtinin. C, Microvessel density (MVD) was quantified based on CD31 staining as previously reported (22). Proliferative index (PI) was quantified based on Ki-67 staining as previously reported (22). Apoptotic index (AI) was quantified based on cleaved caspase-3 staining as previously reported (22). Tiplaxtinin treatment of xenografts was associated with a reduction in angiogenesis and proliferation with an accompanied induction of apoptosis. Data from one representative experiment are presented as mean + SD. *, p < 0.05.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362609199